Testing a new melanoma vaccine after surgery
Part of Cancer, Skin clinical trials.
This study tests whether a new immunotherapy drug (Bmab1800) works as well as Keytruda® to prevent melanoma from coming back after surgery. You'll receive injections over time and be monitored for safety and how your immune system responds.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older with completely removed Stage IIB, IIC, or Stage III melanoma
- Your surgery must have been 4+ weeks ago, and you must start the trial within 12 weeks of surgery
- You have no current cancer elsewhere in your body or spread to the brain
- You have not received any immune checkpoint inhibitor drugs before (like Keytruda, Opdivo, or Yervoy)
- You do not have an active autoimmune disease requiring ongoing treatment in the past 2 years
- You are not taking high-dose steroids or immunosuppressive drugs (except inhaled or topical steroids)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a new biosimilar drug (Bmab1700) works as well as the approved immunotherapy Opdivo (nivolumab) to prevent melanoma from coming back after surgery. You would receive either the biosimilar or Opdivo for about a year, and researchers will compare how your body handles the drug and its safety.
This trial tests whether a combination of two immunotherapy drugs (nivolumab and relatlimab) can clear tiny amounts of cancer cells that remain after surgery in people with high-risk melanoma. It aims to prevent the cancer from coming back.
This trial tests whether giving immunotherapy before surgery and possibly skipping some after may help people with advanced but removable melanoma. It aims to see if this approach can reduce the chance of the cancer coming back.
This trial tests two immunotherapy drugs, ipilimumab and nivolumab, given before surgery for people whose melanoma has come back after previous anti-PD1 treatment. The goal is to see if this combination can shrink the tumor and help prevent future recurrence.
This trial tests whether giving a shorter course of immunotherapy after surgery can help prevent melanoma from coming back. It is for people with high-risk melanoma who have had the cancer fully removed.
This trial tests whether giving pembrolizumab (Keytruda) before surgery helps people with a certain type of advanced melanoma (stage IIb/c). The goal is to see if this treatment can improve outcomes before the tumor is removed.
Hear when a new Adult Patients With Stage IIB, IIC, and Stage III Melanoma Following Complete Resection (Adjuvant Settings) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.